Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
7.7
326.65%
60%
—
135.19%
Every year
—
5 Years
Score7.7
Net Growth326.65%
Net Trend60%
Net Income Consistency—
Rev Growth135.19%
Rev TrendEvery year
Revenue Consistency—
ACADIA Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 441M to $ 1.07B and net income went from -$ 281M to $ 391M. Revenue increased in every one of those 5 years; net income in 3.
Between 2005 and 2025, revenue grew from $ 10M to $ 1.07B and net income went from -$ 34M to $ 391M. Revenue increased in 14 of those 20 years; net income in 9.
ACADIA Pharmaceuticals Inc currently holds a 20-year HDB Score of 4.7 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 29.45 | — |
1 Year2025-08-12 | $ 25.45 | 15.72% |
5 Years2021-08-12 | $ 18.04 | 63.25% |
10 Years2016-08-12 | $ 31.37 | -6.12% |
20 Years2006-08-11 | $ 5.39 | 446.38% |
All Time2004-05-27 | $ 6.70 | 339.55% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | All Time2004-05-27 |
|---|---|---|---|---|---|---|
| Price | $ 29.45 | $ 25.45 | $ 18.04 | $ 31.37 | $ 5.39 | $ 6.70 |
| Return | — | 15.72% | 63.25% | -6.12% | 446.38% | 339.55% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 1.13B | $ 380M | $ 956M |
| 2025 | $ 1.07B | $ 391M | $ 819M |
| 2024 | $ 957M | $ 226M | $ 755M |
| 2023 | $ 726M | -$ 61M | $ 438M |
| 2022 | $ 517M | -$ 215M | $ 416M |
| 2021 | $ 484M | -$ 167M | $ 520M |
| 2020 | $ 441M | -$ 281M | $ 631M |
| 2019 | $ 339M | -$ 235M | $ 697M |
| 2018 | $ 223M | -$ 245M | $ 473M |
| 2017 | $ 124M | -$ 289M | $ 341M |
| 2016 | $ 17M | -$ 271M | $ 529M |
| 2015 | $ 61K | -$ 164M | $ 215M |
| 2014 | $ 120K | -$ 92M | $ 322M |
| 2013 | $ 1M | -$ 37M | $ 185M |
| 2012 | $ 4M | -$ 20M | $ 107M |
| 2011 | $ 2M | -$ 22M | $ 31M |
| 2010 | $ 42M | $ 15M | $ 37M |
| 2009 | $ 6M | -$ 45M | $ 47M |
| 2008 | $ 1M | -$ 64M | $ 60M |
| 2007 | $ 7M | -$ 56M | $ 126M |
| 2006 | $ 8M | -$ 45M | $ 83M |
| 2005 | $ 10M | -$ 34M | $ 43M |
| IPO2004 | $ 4M | -$ 25M | $ 35M |
Explore beyond ACAD
You're looking at ACADIA Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
